Advaxis, Inc. Granted a Qualifying Therapeutic Discovery Project Credit Totaling $244,479 for Advaxis’ Lead Construct Candidate ADXS11-001

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company’s lead immunotherapeutic construct totaling $244,479.
MORE ON THIS TOPIC